Drugs used to treat diabetes and obesity, or GLP-1 (Glucagon-like peptide-1), will be a significant growth driver for ...

Individual usage of glucagon like peptide 1 receptor agonists reduced the risk of hospitalization due to alcohol and substance use disorders.

A slowdown of the digestive tract (gastroparesis) can be a serious side effect, though. Researchers who analyzed the health records of 16 million people revealed that pancreatitis and bowel ...

Randomised controlled trials and real word evidence have consistently shown that GLP-1 receptor agonists are effective and ...

A recent New York Times story described a new fad: "microdosing" GLP-1 anti-obesity drugs like semaglutide (Ozempic, Wegovy) ...

Studies suggest that semaglutide reduces heart attack and stroke and may curb addiction and more. Scientists reflect on the future of GLP-1 drugs beyond weight loss.

GLP-1 agonists substantially slowed kidney deterioration and failure, independent of diabetes status. The most extensive and ...

The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects.

As new research suggests those taking GLP-1 drugs have fewer hospitalisations for alcoholism, a leading specialist warns ...

They’ve been heralded as the magic drugs that treat obesity when diet and exercise have failed. But Ozempic and Wegovy – and ...

From cost-effectiveness of procedures to disc replacement outcomes, researchers published multiple findings about spine surgery in 2024.

The trial was investigating the use of vagus nerve stimulation (VNS) for inflammatory bowel disease (IBD), an autoimmune ...